It's frankly more difficult to find overvalued health care stocks today than undervalued ones, assuming that the market can transition through this dry spell and that procedure volumes pick up with an eventual economic recovery. Given that Hologic (Nasdaq:HOLX) serves markets largely seen as mature, many investors question whether the company can grow fast enough to be worthwhile. Although that is a legitimate concern, investors have become pessimistic to a point where even modest growth could lead to a strong rebound in the stock.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

A Respectable End to the Year
Hologic's business is a combination of solid higher-growth businesses and some smaller, more sluggish operations. Overall growth rose 9% this quarter, with breast health and diagnostics up 11 and 12% respectively, while the surgical and skeletal health businesses grew 1 and 2%. Given that this is still a pretty unhealthy market for capital equipment and doctor office visits, these are pretty solid results. (For related reading on heath care, see How To Avoid Medical Debt.)

On the profitability side, Hologic did OK, but less well. There are a couple of different ways to calculate Hologic's gross margin (depending on whether an investor wants to factor in all of the amortization), but the company posted a half-point (or better) improvement in gross margin either way. Further down the line, adjusted operating income rose 7% as the company swallowed some higher acquisition integration costs and costs tied to a direct marketing campaign for its NovaSure product.

Tomo Starting Strong
Hologic has long been counting on advanced technology (tomosynthesis) to help it stand out better from General Electric (NYSE:GE) and Siemens (NYSE:SI) in the mammography market. So far, it seems to be going well, as the company is seeing surprisingly strong acceptance. Better still, reimbursement for procedures using the new equipment has been favorable, though any investor familiar with service companies like Lincare (Nasdaq:LNCR) or even other device companies like Stryker (NYSE:SYK) can attest to how reimbursement can change quickly.

Can Hologic Maintain Diagnostics Growth?
It was encouraging to see 16% volume growth in the company's ThinPrep diagnostics product. That said, this is a market that is getting more and more crowded. Abbott (NYSE:ABT), Becton Dickinson (NYSE:BDX), Qiagen (Nasdaq:QGEN) and Siemens all want a piece of this lucrative recurrent market, and Gen-Probe (Nasdaq:GPRO) is coming out with a new product of its own. Making matters worse, there's conflicting guidance on just how often women need certain routine tests and confusion could stall market growth.

Moving Abroad
To management's credit, Hologic has been positioning itself for more overseas growth. It is certainly true that there are still many women in developed countries that do not get routine mammograms or gynecological tests, but that pales in comparison to the under-penetration of emerging markets (where, in many cases, some people never see a doctor for routine care). As countries like China, India, and Brazil develop and improve their health care systems, this should become a sizable growth opportunity.

The Bottom Line
There's plenty already out there on the poor state of routine health care procedure volumes, and it affects both Hologic and its competitors like Johnson & Johnson (NYSE:JNJ), Bard (NYSE:BCR) and Abbott. It is not at all likely to be a permanent situation, though. If the economy improves and unemployment goes back to a more historically normal level, it stands to reason that health care utilization will rebound. In the meantime, Hologic has a growing overseas business and the opportunity to do more deals in the meantime.

If Hologic can deliver mid-single-digit revenue growth and gradual margin improvement, the stock is under-priced to a meaningful degree. The Street would no doubt like to see more obvious growth market opportunities for Hologic, but patient investors could well be rewarded with the as-is business at this women's health specialist. (For related reading, see Investing In The Healthcare Sector.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Stephen Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  2. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  3. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  4. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  5. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  6. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  7. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  8. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  9. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  10. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center